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ABSTRACT

Influence of Carbon Sources on the Pathogenicity of Mycoplasma pneumoniae (Spring 2020)

Travis Anthony Salinas, Texas A&M International University;

Chair of Committee: Dr. Michael R. Kidd

Mycoplasma pneumoniae is a human respiratory tract pathogen and one of the bestcharacterized minimal bacteria. It is a serious problem because of health problems it can cause as
it can be detrimental to humans and the occurrence and aggravation of systemic involvement in
M. pneumoniae infection occur via multiple immunological pathways. With its major source of
carbon and energy coming from phospholipids, Mycoplasma pneumoniae thrives on lung epithelia.
In Mycoplasma pneumoniae, pathogenicity is closely related to carbon metabolism. By testing
carbon sources in well plates and growth curves to analyze how growth is affected in Mycoplasma
pneumoniae and measure optical density, carbon source effectiveness may be better understood.
The hypothesis of this study is that other carbon sources similar to glycerol and glucose, such as
mannose and sorbose, can be beneficial to the growth of Mycoplasma pneumoniae as well. With
the use of well plates and culture flask, growth curves were developed to measure growth with
optical density. Glucose and glycerol were shown to be carbon sources that were able to use by
Mycoplasma pneumoniae, with carbon sources such as maltitol and xylitol showed positive results.
The hypothesis in this study was shown to be not supported. While other carbon sources were able
to be utilized by Mycoplasma pneumoniae, they were not as efficient as glucose and glycerol.
Maltitol was a carbon source uncharacteristically grew with Mycoplasma pneumoniae. A two-way
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ANOVA that was done testing No Carbon Source against other carbon sources showed that
glucose was the only carbon source that was significant. A two-way ANOVA of glucose against
other carbon sources showed they were all significant, except for maltitol. It can be assumed with
the data that hexose sugars, pentose sugars, and sugar alcohols that are similar to glucose and
glycerol can be used by these lung bacteria. In turn, theoretically these carbon sources can be used
to develop alternate treatments to treat afflictions that infect the lungs. In time, these carbon
sources can be possibly be used to counter diseases and difficulties caused by Mycoplasma
pneumoniae.
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INTRODUCTION
There are more than 200 known species in the genus Mycoplasma. Belonging to the class
Mollicutes, a group of bacteria that have been evolved from a common gram-positive ancestor
with low GC content (1). This bacterium has recently attracted considerable interest as a model
organism in synthetic and system biology (2). Although the term Mycoplasma is widely used to
refer to any organism in the class Mollicutes, only four species – Mycoplasma pneumoniae,
Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum – are known to be
human pathogens (3, 4). Mycoplasma pneumoniae is a human respiratory tract pathogen and one
of the best-characterized minimal bacteria (5). It is a rod-shaped bacterium and is one of the most
common causes of atypical pneumonia in the United States, usually transmitted from person to
person via respiratory droplets with an incubation period average of two to three weeks (6). As it
has no bacterial cell wall, antibiotics that inhibit DNA synthesis, such as macrolides,
fluoroquinolone, and tetracycline, are commonly used to treat infections (7-9). It is also one of the
smallest self-replicating organisms that is able to grow independently from any hoist cell, with the
entire machinery of the cell being increasingly more known in recent years due to increased
research (10-12). It has shown to be a significant respiratory pathogen that is most common seen
in children and the elderly, resulting in over 100,000 adult hospitalizations every year in the United
States (3, 4). Mycoplasma pneumonaie is the causative agent of atypical pneumonia. It also causes
a wide array of extrapulmonary infections – such as encephalitis, optic neuritis, acute psychosis,
stroke, cranial nerve palsies, aseptic meningitis - and it has been implicated in immune mediated
neurological diseases such as acute demyelinating encephalomyelitis, Guillain-Barre syndrome
and transverse myelitis (13) - and autoimmune phenomena (14). While it is most common to see
respiratory tract symptoms be a cause of Mycoplasma pneumoniae, extrapulmonary indications
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are not uncommon (15). It is also known that it causes cardiovascular, hematologic, dermatologic,
hepatobiliary, and neurologic systems in children, which is occur as difficulties after pneumonia
(16-18).
Among the genital mycoplasmas, Ureaplasma species are the most prevalent, potentially
pathogenic bacteria isolate from the urogenital tract of both women and men (19). It penetrates the
submucosa only during immunosuppression or instrumentation transmitted through sexual contact.
It is also able to be transmitted from the mother to offspring vertically in the utero or through
infected body fluids at the time of birth (19). Their involvement in the hyperactive bladders and
interstitial cystitis and painful bladder syndrome is controversial. In most cases their role in any
particular pathology cannot be proven, only theorized (20). Belonging to family
Mycoplasmataceae and the class Mollicutes, it was first discovered in 1954 by Maurice Shepard
(19). Since they produce small colonies, 7-15 micrometers in diameter, they were originally call
T-strain Mycoplasmas. It was eventually considered to be unique among Mycoplasmas of human
origin; thus, it was proposed that a new genus and species designation was to be made, now called
order Mycoplasmatales. They were named Ureaplasma urealyticum by Maurice Shepard in 1974
(19). In general, the knowledge of how mycoplasma and Ureaplasma species in the urogenital tract
is lacking, with not that much literature on the topic as of now, specifically dealing with its impact
on women. Further studies are urgently needed (20).
Mycoplasma pneumoniae is particularly instructive, as it features an attachment organelle
(AO) or terminal organelle, a polar extension of the cell involved in adherence, motility, and cell
division (21). Its mechanisms, regulation, and construction have been studied, which show that
various aspects of its basic biology and its pathogenicity are at the heart of major cell biological
issues concerning M. pneumoniae. Pathogenic mycoplasmas, such as Mycoplasma pneumoniae,
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have evolved strategies to survive specific environments in their hosts. This process of surviving
in the lungs involves mechanisms; for example, the loss of unnecessary genes via reductive
evolution that allow essential genes in the mycoplasma to be able to survive longer (22). Another
way this bacterium has adapted for survival in developing different pathways of transmission (23).
Its pathogenicity is linked to carbon metabolism, using glucose and glycerol and primary carbon
sources (24).
Mycoplasmas have a been known to be simple organisms when; however, studies have
shown that this is not true. Having undergone reductive evolution from their ancestors,
mycoplasma genomes are less complex than other bacteria and are capable of being grown in
laboratory setting, which makes them a model organism (21). Their small genome size results from
the loss of major anabolic pathways and reduction in the complexity of gene expression regulation.
This can include assembly of macromolecular structures, adherence, cell polarity, cell division,
and motility (21).
Mycoplasma pneumoniae is known to have a loss of the cell wall as a result of reductive
evolution. It retains 54 of the 105 genes that are associated with cell wall construction, which may
suggest that reductive evolution is ongoing (26). The loss of certain gene sets, such as lipid
metabolism and amino acid biosynthesis, also shows a need of a transfer of dependence for nutrient
acquisition from host organisms (26). Mycoplasmas seem to have evolved in this direction, from
a large genome to a smaller one with reduced genes. This supports the theory that Mycoplasma
genomes were altered in response to the environment (26).
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Virulence Factors
The formation of hydrogen peroxide, which is a product of glycerol metabolism, is crucial
to host cell cytotoxicity (22). Hydrogen peroxide is a by-product of glycerol metabolism in
mycoplasmas and has shown to cause cytotoxicity for cocultured eukaryotic cells (22). Because of
this, there seems to be discerning pressure for mycoplasmas to preserve the genes needed for
glycerol metabolism, leading to speculation as to their function during infection. Studies have
shown that glycerol metabolism is active in many mycoplasma species, glycerol production and
hydrogen peroxide production have been established to be linked with the virulence of any
mycoplasma in vivo, meaning taking place in a living organism (22).
Asthma is a complex inflammatory disease of the lungs that has reached epidemic
proportions in the developed world (27). As of 2018, it is estimated to affect 300 million worldwide
and 10% of the United States and Europe. Until recently, no virulence factors of Mycoplasma
pneumoniae have been directly linked to asthma pathogenesis (27). Atypical bacterial infections
or colonization with Mycoplasma pneumoniae have been increasingly associated with the
development of asthma and the worsening of asthma control. It has been identified that an ADPribosylating and vacuolating toxin producing by Mycoplasma pneumoniae, community-acquired
respiratory distress (CARDS) toxin, which is strongly linked with Mycoplasma pneumoniaeassociated disease in humans and directly linked to asthma-like inflammatory patterns in animal
models (27). Colonization is seasonal, and CARDS toxin is readily detected in respiratory
secretions in children in the winter months. Approximately 50% of hospitalized children with acute
exacerbation of asthma had detectable CARDS toxin in their respiratory secretions (27).
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Epidemiology
Although Mycoplasma pneumoniae is known to cause community acquired pneumonia, it
has seldom been documented as the causative organism of pneumonia because of the typical mild
clinical course of mycoplasma infection (28). Apart from respiratory tract infections, it also causes
various extrapulmonary manifestations in as many as 25% of patients that have a mycoplasma
infection. Stevens-Johnson syndrome has been associated with M. pneumoniae, with inducing rash
and

mucositis

symptoms

being

shown

as

indications

patients

exhibit

(29-31).

Histopathologically, M. pneumoniae-caused pneumonia is characterized by acute cellular
bronchiolitis with edematous and ulcerative lesions of bronchial walls and by peribronchial and
perivascular interstitial opacities containing lymphocytes, plasma cells, and macrophages (32).
This can also manifest as renal, gastrointestinal, hematological, ocular, and osteoarticular
infections, and appear at various intervals after the initial pulmonary infection. Pulmonary
manifestations that occur are typically tracheobronchitis and pneumonia, with symptoms including
coughing and wheezing (33-35). It can also occur in the absence of respiratory tract symptoms (28,
36). The immunopathogenesis of M. pneumoniae remains unknown, but it has been hypothesized
that excessive immune reaction against the insults from infection is associated with lung cell injury
(37).
Mycoplasma pneumoniae is a serious problem because of health problems it can cause as
it can be detrimental to humans and the occurrence and aggravation of systemic involvement in
M. pneumoniae infection occur via multiple immunological pathways (28). Radiological findings
of this strain of pneumonia are diverse and nonspecific (38). The prevalence of infection with M.
pneumoniae is generally miscalculated, as most patients infected as seldomly symptomatic and
they infrequently seek medical attention (39). Due to advantages of PCR on its sensitivity,
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specificity, and early detection, a sizable range of studies have been published as able to detect M.
pneumoniae (40). Laboratory diagnosis of this bacterial infection in a clinical practice study have
been based on serology, polymerase chain reaction (PCR), and culture, although they have specific
limitations (41). Serology using enzyme immunoassays is the most widely used test for the
diagnosis for the infection, with IgM and IgA antibodies both appear in the early phase of infection
and detection of any or both antibodies indicates an acute infection (42). The clinical aspect and
tendencies observed suggest that higher M. pneumoniae-IgM titer leads to more severe
presentation of diseases, as well as more serious laboratory and imaging changes including Creactive protein, platelets, CT Scans, and chest x-rays (43). These infections seem to primarily
involve pathogen adhesion to respiratory epithelium, followed by direct cell invasion (44). Natural
immunity of M. pneumoniae infections are usually short-term, as evidenced by the frequency of
reinfections in the same person over time, and organisms continue to be shed for variable periods
after resolution of the clinical illness (45). More studies are still needed to understand mycoplasma
infections and how to manage it in early stages to prevent serious ailments (38). M. pneumoniae’s
molecular characteristics are currently scarce, which don’t benefit patients that have been
hospitalized due to it. Researchers have performed molecular characterization of nasopharyngeal
and oropharyngeal swabs from hospitalized children and adults. Results indicate that current
methods are not able to notably distinguish M. pneumoniae because the majority of strains can be
classified into only a few main types. (46). Differences in strain types do not appear to be
associated with variances in clinical outcomes (46).

Whole genome sequencing has been

hypothesized to better identify ways to characterize these strains for better clinical treatment (46).
Mycoplasma pneumoniae infections can encompass both the lower and upper respiratory
tract and occurred worldwide in an endemic fashion with an epidemic spurt at four to seven
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intervals (47). Seasonality, geography, and climate are not thought to be a major consequence.
Most occurrences in the United States tend to occur in late summer and early fall (47). However,
according to Japanese multi-center study, 403 typical pneumonia cases were studied, with 62 were
caused by M. pneumoniae (48). Serological studies, such as studies by Lind et al, shows that M.
pneumoniae has a pattern of endemic disease transmission over a period of 50 years. This is also
punctuated with recurring epidemics every three to five years (47). Relatively large droplets may
be required for transmission as evidenced by close personal contact. This is common in military
barracks, institutions, and schools (47). Outbreaks of this strain of pneumonia is a significant
public health concern since numerous strains exhibiting antibiotic resistance are emerging
worldwide (49).
Mycoplasma pneumoniae has strong clinical associations with asthma exacerbations and
morbidity in both children and adults (40). This strain of pneumonia causes up to 40% or more of
community acquired pneumonia (CAP) cases and as many as 18% of cases requiring
hospitalizations in children and young adults (47, 50-53). This strain of pneumonia is responsible
for 15-20% of all cases of community-acquired pneumonia and cause of hospitalization and
mortality in Chinese children (54). Infection with M. pneumoniae is mostly seen in outpatient
settings and it is a significant cause of hospitalization due to pneumonia, especially in the elderly
and immunocompromised patients (55). Although adults are not frequently affected, there are
5.6% of cases associated with respiratory failure that require ventilator management (56). It also
accounts for 10 to 30% of all community-acquired pneumonia (57, 58). Fortunately, it has a lesser
occurrence in children under 3 years old (59). M. pneumoniae is also detected as frequently as
Streptococcus pneumoniae and Haemophilus influenzae (60). A common method of detection that
has been used frequently is Real-time polymerase chain reaction (RT-PCR) (61). Studies have
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shown the M. pneumoniae strains are unusual in children less than five years. However, the risk
of infection is shown to be in children age 5-15, decreasing after youth and into adulthood. Older
individuals and young children under the age of 5 also may have M. pneumoniae occur endemically
and sporadically epidemically. Serological studies in Denmark over a 50-year period showed that
infections exhibit epidemic periodicity every 3-5 years (62). It often spreads through close contact
in families, with the epidemic happening every 3 to 7 years, with the most recent one happening
in Korea in 2016 (63, 64). Early and rapid diagnosis of interstitial pneumonia due to M.
pneumoniae is of significance since certain antibiotics are unsuccessful against it (65). This strain
of pneumonia is regularly a self-limiting disease, but some patients complain of getting a
progressively severe pneumonia that is not responsive to antibiotic treatment (66). Factors
normally associated with M. pneumoniae are vomiting diarrhea, and persistent cough have been
identified as symptoms (67). Although M. pneumoniae is generally nonthreatening and selflimiting, numerous studies have specified that it can progress into severe deadly diseases such as
acute respiratory distress syndrome, necrotizing pneumonitis, and fulminant pneumonia in
children 5- 15 years (68). A condition known of central retinal artery occlusion (CRAO) is an
arterial ischemic stroke, hardly happened in children inflicted with asymptomatic cerebral
infraction and almost never involved in severe pneumonia related to M. pneumoniae infection (69).
Respiratory disease caused by Mycoplasma pneumoniae comes from the close association
between the organism and the mucosal epithelium that occurs as a result of cytoadherence, which
is considered as a major virulence factor (4). Subsequent to cytoadherence, it is also believed to
partly cause disease through generation of peroxide and superoxide radicals. These act together
with endogenous toxic oxygen molecules generated by the host to induce oxidative stress (4). The
superoxide anions produced by M. pneumoniae act to inhibit catalase in host cells, resulting in
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reducing the enzymatic breakdown of peroxides at the point of origin. It is also reducing the
enzymatic breakdown by the mycoplasma, rendering the hoist cell more vulnerable to oxidative
harm (4). General physicians commonly encounter patients with M. pneumoniae-caused
pneumonia who have a disproportionately low level of respiratory distress compared to the extent
of lung involvement. This has caused concerns regarding the diagnostic process of M. pneumoniaecaused pneumonia (37).
Mycoplasma pneumoniae may also be implicated in immune mediated neurological
diseases (13). Central nervous system infections and inflammatory or autoimmune disorders may
cause secondary central nervous system vasculitis. Mycoplasma may cause secondary central
nervous system vasculitis in children. In studies by Yimenicioğlu, S., et al. (13), one of their
patients with encephalitis also had vasculitis of internal carotid artery and posterior circulation.
Their conclusion in their tests came to that while neurological manifestations associated with
Mycoplasma pneumoniae usually resolve completely, they also can result in chronic debilitating
deficits in motor and mental function with various degrees of life-threatening complications
(70). Neurological complications occurred in 11.5% of children hospitalized in our institution with
PCR-confirmed M. pneumoniae infection (71). Recent studies demonstrated that the incidence of
fatal or severe M. pneumoniae is gradually increasing which might be related to the excessive
inflammation. However, the exact pathogenesis of this excessive inflammation is still unclear (72).
A mutual opinion in the treatment of Mycoplasma pneumoniae is that it really does not
matter where any antibacterial solutions were given because the mortality rate is low and the
infections it causes are often self-limiting (47, 73). However, studies from as early as the 1960’s
indicate that the treatment for mild M. pneumoniae infections do reduce the morbidity of
pneumonia and shortens the duration of symptoms shown. In a Japanese study, telithromycin, a
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ketolide antibiotic was found to have a good activity against 41 clinical isolates of Mycoplasma
pneumoniae (47). Macrolide-resistant Mycoplasma pneumoniae have also been reported
worldwide as a focus as well (74). Since 200, the emerging of macrolide-resistant M. pneumoniae
has been reported in China, Japan, Europe, and United States, affecting both children and adults
(75, 76). Various antibiotics have been developed to react to the infections it may cause, with
numerous developed depending on the age of the patients involved in the infection. Drug resistant
M. pneumoniae is also a rising issue in the management of community-acquired pneumonia, as
epidemiological monitoring is important for classifying resistant patterns of M. pneumoniae
against several antibiotics in adult community-acquired pneumonia patients (77).

Carbon Metabolism
For Mycoplasma pneumoniae and other human pathogens, including Mycobacterium
tuberculosis or Listeria monocytogenes, glycerol, glycerol-containing lipids, and glucose are the
ideal carbon sources (2). In lung epithelium, the main habitat of Mycoplasma pneumoniae, the
bacteria use available carbon sources in the surfactant, primarily phospholipids. Since
phospholipids are the most plentiful potential carbon source for Mycoplasma pneumoniae living
on lung epithelial surfaces, the possibility that these bacteria synthesize enzymes to cleave polar
head groups from the glycerophosphodiesters to produce glycerol-3-phosphate that can be utilized
by the enzymes of glycerol metabolism has been considered (77).
With its major source of carbon and energy coming from phospholipids, Mycoplasma
pneumoniae thrives on lung epithelia (25). In Mycoplasma pneumoniae, pathogenicity is closely
related to carbon metabolism (24). Cumulative information on the pathogenesis of human
Mycoplasma pneumoniae-caused pneumonia to have been gathered from pathological
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examination of autopsy specimens (78). The chemical properties of other carbon sources affect the
growth of Mycoplasma pneumoniae is not well known.
A study on carbon sources common to the lungs, where M. pneumoniae is most known to
infect human hosts, would be beneficial to treating these afflictions. There appears to be selective
pressure for mycoplasmas to retain their genes needed for glycerol metabolism. Experimental and
clinical studies have implied that the pathogenesis of lung injuries in Mycoplasma pneumoniae
infection is linked to cell-mediated immune reaction, and high receptiveness to corticosteroid
therapy have been stated, specifically for severe diseases (79). In comparison to copious amount
of published studies on the carriage of Streptococcus pneumoniae in children, a more common
strain of pneumonia, studies that exclusively address asymptomatic carriage of Mycoplasma
pneumoniae has not be been well researched (80). If studies can figure out carbon sources that
can affect the growth of lung bacteria, then various medicines and treatments can be clinically
tested to better help patients. Carbon sources - such as hexose sugars, pentose sugars,
disaccharides, trisaccharides, alcohol sugars, sugar acids, amino acids, and fatty acids – can be
tested to see the effectiveness in growth of the bacteria.

Glycerol Metabolism
The pathway of glycerol utilization is of great importance for Mycoplasma pneumoniae
and related species not only due to relevance of glycerophospholipids as a major carbon source,
but also since it generates hydrogen peroxide as a major virulence factor (81). Mycoplasma
pneumoniae possesses the complete set of genes for glycerol utilization, and the bacteria do use
this a carbon source (24). GlpF is the glycerol uptake facilitator, and GlpK and GlpO metabolize
glycerol to the glycotic intermediate dihydroxyacetone phosphate. Hydrogen peroxide that forms
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by GlpQ is important for the effects of M. pneumoniae cytotoxicity (12). Glycerol metabolism is
under dual control, as the genes involved in glycerol utilization are expressed only if glycerol or
glycerol 3-phosphate is present in the medium, and they are not expressed in the presence of
glucose, the preferred carbon source (24).

FIG 1: shows an illustration of metabolic pathway for the uptake and conversion of carbohydrates leading to the
formation of glycerol-3-phosphate in Mycoplasma pneumoniae (25).

Mycoplasmas must acquire macromolecular precursors and high-energy compounds, such
as sugars from their environment. This is done to maintain their life cycle and to produce active
metabolic intermediates (90). Glycerol is one of the few carbon sources that can be used efficiently
by Mycoplasma pneumoniae (24). Researchers have analyzed genes involved in glycerol
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metabolism and detected constitutive expression in the presence of glycerol or selected carbon
sources. The enzymes of glycerol metabolism are critical for the pathogenicity, but also for other
currently undisclosed functions of the cell (24).
The newly identified GlpU transport protein is responsible for the uptake of the
glycerophosphodiester glycerophosphocholine (25). Data suggests that the proteins MPN133 and
MPN 284, may act as binding proteins for glycerol and deliver glycerol molecules to the glycerol
facilitator GlpF (25). Other studies show that there appears to be no link between glycerol
metabolism, hydrogen peroxide, cytotoxicity, and virulence in Mycoplasma species in a natural
host (12).
In Mycoplasma pneumoniae, as well as other Mollicutes, pathogenicity is closely linked to
carbon metabolism (24). Glycerol being a major carbon source involves the oxidation of glycerol
3-phosphate oxidase, which produces hydrogen peroxide rather than NADH 2, which is generated
by glycerol 3-phosphate dehydrogenase in most other bacteria. In addition to the induction of
autoimmune responses, the formation of hydrogen peroxide is the only established mechanism by
which mycoplasmas cause damage to their hosts (24).
For the colonization of epithelial lung cells, Mycoplasma pneumoniae has developed different
mechanisms for attachment, virulence, and utilization of host-derived metabolites (2). This is
where its utilization of glucose, fructose, and glycerol as a carbon source come into the picture.
These carbohydrates are catabolized via glycolysis as the major pathway for ATP generation, and
this is very important as high efficiency is crucial. The importance of glycolysis for Mycoplasma
pneumoniae and other mollicutes un underlined by the lack of the oxidative part of the pentose
phosphate pathway and of the citric acid cycle (2).
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Scientists have explored the interactions between glycolytic enzymes using the bacterial
adenylate cyclase-based two-hybrid system and determined that most of the glycolytic enzymes
perform self-interactions (82). Furthermore, enolase as the central glycolytic enzyme of M.
pneumoniae was able to be identified due to its ability to directly interact with all other glycolytic
enzymes. Results support the idea of the development of a glycolytic complex in M. pneumoniae
(82). The formation of this complex might ensure higher fluctuations through the glycolytic
pathway than would be possible with isolated non-interacting enzymes (82).
Mycoplasma pneumoniae

contains MPN420 (GlpQ), which is the only active

glycerophosphodiesterase. GlpQ metabolizes in this organism glycerophosphocholine from the
lung to generate free choline. Chlorine also serves as a substrate for renewed synthesis of
phosphatidylcholine. Glycerol-3-Phosphate is also a product of this reaction. While all of this data
that has been discovered is not directly contributed to Mycoplasma, infection with GlpQ2 mutant
decreased the severity of pneumonia compared with the parent strain (83). GlpQ2 also develops
surface phosphorylcholine expression, which contributes to the severity of pneumonia by
stimulating adherence and host cell cytotoxicity (84).

GlpQ gene expression levels were

noticeably higher than in under other growth conditions (83).
In Mycoplasma pneumoniae, GlpQ is not only important for virulence but also growth in
the commonly used medium in the laboratory, such as Hayflick medium with glucose as the added
carbon source (12). Studies by Schmidl et al (12), no difference between the wild type strain and
the GlpQ mutant was observed during the growth in the presence of glycerol. Carbon metabolism
is linked to virulence in pathogenic bacteria, including Mycoplasma pneumoniae and other
mollicutes, and the utilization of glycerol and phospholipids play a significant role in the virulence
of Mycoplasma pneumoniae and other mycoplasma species. Hydrogen peroxide, which was
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mentioned before as the major cytotoxic substance produced by these bacteria, is generated as a
product of glycerol metabolism, and both GlpD and GlpQ mutants are severely affected in
pathogenicity (12).
Even with this known pathway, Mycoplasma pneumoniae still lacks many other metabolic
pathways, forcing it to acquire the necessary building blocks, amino acids, nucleobases, and fatty
acids, from its environment (85). Accurate representation of cellular networks through
mathematical models is central goal of a discipline such as integrative systems biology, the study
of disease and how it affects at systems level (85). For example, ATP generation is completed by
simple organic acid fermentation because of the absence of the TCA cycle and a functional
respiratory chain. The absence of most pathways and anabolic processes make M. pneumoniae an
ideal organism to study basic metabolic functions and study its energy charges (86).
The lack of most anabolic processes and rescue pathways known for more complex
organisms and the predictable high linearity of its metabolic network make Mycoplasma
pneumoniae an model organism to study essential metabolic functions and analyze energy
expenses (86). Studies have shown that the main subsystems of the metabolic network are energyproducing pathways, amino acid, nucleotide, lipid, and cofactor metabolism, as well as transport
reactions. Wodke et al. (86), found in their studies that flux activity analysis at diverse time points
of the exponential growth phase and in silico knock-outs, or in a computer simulations, coincide,
signifying that the same metabolic pathways are responsible for adaptation in Mycoplasma
pneumoniae, namely the nucleotide metabolism and pentose phosphate pathway. Metabolic gene
essentiality analysis also identified the genes connected with main catabolic pathways – the
glycolysis + pentose phosphate pathway – among the non-essential genes as most vital for
metabolic performance. This further shows the simplicity of the metabolic network of Mycoplasma
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pneumoniae (86).
Carbon sources refer to any carbon contain molecule - carbohydrate, amino acid, fatty acid,
carbon dioxide – used by an organism for the synthesis of its organic molecules. Carbon is a basic
element for sustain life and is mainly used for cell growth and product formation. Mycoplasma
pneumoniae shows the fastest growth with glucose (23). For the colonization of epithelial lung
cells, M. pneumoniae has developed different mechanisms for attachment, virulence and utilization
of host-derived metabolites, utilizing glucose, fructose, and glycerol as a carbon source (87) These
carbohydrates are catabolized via glycolysis as the major pathway for ATP generation. Glycolysis
for M. pneumoniae and other mollicutes are significant, so high efficiency is essential (87).
Phospholipids and derived metabolites, such as glycerol, are the major sources of carbon and
energy for the bacteria on lung epithelia. The oxidation of the common intermediate glycerol 3phosphate gives rise to the production of hydrogen peroxide, which is a major factor in the
virulence in Mycoplasma pneumoniae.
With the use of these sugars, the possibility of other hexose sugars being successful is
worth studying. Other hexose sugars, such as galactose, mannose, rhamnose, and sorbose, may
also yield results that show they can also be utilized. Additionally, other carbon sources like
pentose sugars and alcohol sugars need to be tested to see their effect on Mycoplasma pneumoniae
growth and pathogenicity. In laboratory experiments, Mycoplasma pneumoniae can be grown in
rich and defined medium. In both conditions, it metabolizes glucose as a major carbon and energy
source (85). A variety of other reduced carbon compounds, such as fructose, mannose, ribose,
ascorbic acid, glycerol, glycerol 3-phosphate, and glycerolphosphocholine can be metabolized
(85).
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Two things this study will be examining in Mycoplasma pneumoniae are carbon source
metabolism by testing bacteria using bacterial well plates and by cell growth curves. By testing
carbon sources in well plates and growth curves to analyze how growth is affected in Mycoplasma
pneumoniae and measure optical density, carbon source effectiveness may be better understood.
The hypothesis of this study is that other carbon sources similar to glycerol and glucose, such as
mannose and sorbose, can be beneficial to the growth of Mycoplasma pneumoniae as well. If more
carbon sources are revealed to be advantageous to lung bacteria such as Mycoplasma pneumoniae,
then professionals in the medical field will have more data to be able to create improved treatments
to combat these carbon sources that aid infectious bacteria.
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RESULTS
Carbon Source Utilization
Carbon sources in this study were chosen based on their similarities to glucose and
glycerol. Hexose sugars and sugar alcohols, such as fructose and mannitol, were tested in well
plates and culture flasks and incubated at 37°C to allow for Mycoplasma pneumoniae to growth
with the inoculated carbon source. Day cycles are needed to see how over six to eight days the
trend these carbon sources go through. The well plates were photographed on certain days to see
how the well and the various concentrations affect Mycoplasma pneumoniae. Each well plate has
the medium and the correct carbon source in it. The contents of each well starts out the color of
the Hayflick medium, which is red. If the color turns lighter, such as an orange or yellow, this
signifies that the carbon source is reacting favorably with Mycoplasma pneumoniae. If the color
turns darker, such as purple or black, this means that it is overkilling the bacteria, making it unable
to thrive. The cell culture flasks were photographed in two-day periods to track their growth and
then tested at the end of day eight. A spectrophotometer was used to measure the optical density
of these carbon sources, with the starting OD being 0.01.
Two phases of methodology were done to test carbon sources: testing well plates to see
change in color and cultivating culture flasks to test optical density. With glucose being a known
carbon source that Mycoplasma pneumoniae is able to utilize, many other carbon sources have
been shown to also be useful in the processes it needs. A variety of additional reduced carbon
compounds, such as fructose, mannose and ribose can be metabolized (85). Mannitol has a reduced
amount of growth and cannot be utilized by Mycoplasma pneumoniae, even though a utilization
pathway has been predicted (86).
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Well plates with several sugar alcohols were tested to see how Mycoplasma pneumoniae
would react in different concentrations in the incubator. MPN in ribose showed the most growth
over the six-day period, with xylose showing a little growth as well. MPN in arabinose, sorbitol,
mannitol, and glycerol demonstrated little to no growth, even in the diverse concentrations they
were tested in. Assumptions that can be from these results is that Mycoplasma pneumoniae can
utilize ribose and xylose in some way for its various processes.

Hexose Sugars

FIG 2: Hexose sugars well plate. Sugar concentrations are as indicated: 0, 0.1, 0.25, 0.50, 1, 2.5, 5, and 10.
From pictures top to bottom: Day 2, Day 3, Day 4, Day 5.

By Day 2, glucose, fructose, and mannose have grown in concentrations 0.25 and higher
(Figure 2). Galactose has seen some growth, but rhamnose and sorbose show no growth at all. Day
3 growth shows that Galactose starts to be utilized by Mycoplasma pneumoniae in a more efficient
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way, while glucose, fructose, and mannose are stable. Day 4 and day 5 have the top four carbon
sources stable out in their growth, showing that an eight-day cycle is effective. Rhamnose and
sorbose show little to no growth over the cycle.
Hexose sugars were tested at different concentrations to see how they would affect over
several days in an incubator. MPN in glucose grew the fastest, as by Day 4 the color of the well
was already yellow in the wells with 0.5% or higher concentrations. MPN in mannose showed the
second most growth of the hexoses tested, turning orange by Day 4 when exposed to Mycoplasma
pneumoniae. MPN in fructose is the 3rd hexose that showed some growth through the days in the
conditions in the incubator, specifically the higher concentrations tested. MPN in galactose,
rhamnose, and sorbose showed little to no growth, even by Day 10. From these results it can be
assumed that Mycoplasma pneumoniae will react similarly with mannose and fructose as it does
with glucose, albeit not as well as glucose.

Pentose Sugars

FIG 3: Pentose sugars well plate. Sugar concentrations are as indicated: 0, 0.1, 0.25, 0.50, 1, 2.5, 5, and 10.
From pictures top to bottom: Day 2, Day 4, Day 10, Day 14.
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Figures 3 shows that growth for sugar alcohols are not as proficient hexose sugars. Ribose,
and to a lesser extent xylose, start to show growth by Day 10 at concentrations of 1 or higher.
Arabinose, sorbitol, mannitol, and glycerol show little to no growth over a two-week timeframe.
Glycerol does show growth by day 14, but the time it takes to get any growth with the current
concentrations is not an effective use of a carbon source.

Sugar Alcohols

FIG 4: Sugar Alcohols well plate. Sugar concentrations are as indicated: 0, 0.1, 0.25, 0.50, 1, 2.5, 5, and 10.
From pictures top to bottom: Day 2, Day 4, Day 6, Day 10.

Figure 4 shows xylitol, dulcitol, and inositol show little to no growth over a ten-day cycle.
On day 10, there seems to have a little growth for the sugar alcohols. However, the growth is not
as efficient as other carbon sources, such as glucose and fructose.
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Hexose Sugars Growth Curves

FIG 5: A graph of hexose sugars being tested against No Carbon Source. For all carbon sources in the figure, 3 of the
trials were put together to show a standard deviation for each hexose sugars. All the carbon sources – Glucose,
Fructose, Mannose, Rhamnose, Sorbose, Galactose, and Fucose – were then graphed out over the 6-day cycle at OD500.
Concentrations of carbon sources are as indicated: 40% Fructose; 25% Mannose, Rhamnose, Sorbose, Galactose,
Fucose; & 50% Glucose.

Glucose showed the most growth over a six-day growth curve cycle than the other hexose
sugars. Glucose seems to more efficient that the others, although the other carbon sources are not
any less significant. Fructose, mannose, rhamnose, sorbose, galactose, and fucose all had growth
over the six days, but they were all about the dame range by Day 6. Glucose, as other studies have
stated, seems to be one of the most efficient carbon sources for Mycoplasma pneumoniae.
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Pentose Sugars Growth Curves

FIG 6: A graph of pentose sugars being tested against No Carbon Source. For all carbon sources in the figure, 3 of
the trials were put together to show a standard deviation for each pentose sugars. All the carbon sources – Arabinose,
Xylose, Ribose – were then graphed out over the 6-day cycle at OD500. Concentrations of carbon sources are as
indicated: 25% Arabinose. Xylose, & Ribose.

Arabinose, xylose, and ribose all has similar trajectories in the six-day growth curve cycle.
Ribose had the most growth on day 2, but over the next four days arabinose and xylose evened out
around the same range as ribose. Compared to glucose, the growth is significant as glucose grew
considerably more than the pentose sugars. Mycoplasma pneumoniae was able to utilize the carbon
sources in the culture flask environment, but not as well as some of the hexose sugars.
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Sugar Alcohols Growth Curves

FIG 7: A graph of sugar alcohols being tested against No Carbon Source. For all carbon sources in the figure, 3 of the
trials were put together to show a standard deviation for each sugar alcohols. All the carbon sources – Glycerol,
Dulcitol, Inositol, Maltitol, Mannitol, Sorbitol, & Xylitol – were then graphed out over the 6-day cycle at OD500.
Concentrations of carbon sources are as indicated: 10% Dulcitol, Inositol, Maltitol, Mannitol, Sorbitol, & Xylitol; &
50% Glycerol.

Over the six-day growth curve cycle for sugar alcohols, maltitol had the most amount of
growth of them. However, the growth of the other carbon sources was not any less proficient as
maltitol. Glycerol and dulcitol has almost the same amount of growth by day 6, with xylitol having
the least amount of growth. Sugar alcohols such as xylitol and inositol seem to have a decreased
at certain points in the cycle, showing that possibly Mycoplasma pneumoniae was done utilizing
the carbon source, or no more was able to be used at the point in the cycle. While the sugar alcohols
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grew in mostly positive way, they were still not as efficient as glucose or some of the hexose
sugars.

All Carbon Sources Growth Curves
Figure 8 shows all the carbon sources in the same graph to show the comparison between
all the carbon sources in the groups together. Figures 9-11 show the Day 2, Day 4, and Day 6
growth respectively.

FIG 8: A graph of all carbon sources compared to each other. For all carbon sources in the figure, 3 of the trials were
put together to show a standard deviation for each. All the carbon sources were then graphed out over the 6-day cycle
at OD500.
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Six-Day Cycle Comparisons

FIG 9: A graph showing all the data points for Day 2 of the cycle for all carbon sources .

The Day 2 growth curves (Figure 9) for the carbon sources in the groups show a wide range
of values. While glucose and glycerol are known to be major carbon sources for Mycoplasma
pneumoniae to utilize, dulcitol has the most growth on day 2 than the other carbon sources.
Mannitol, maltitol and inositol are the next carbon sources with the highest growth after dulcitol.
Curiously, glucose, mannose, and fructose have the lowest growth on day 2 out of the carbon
sources.
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FIG 10: A graph showing all the data points for Day 4 of the cycle for all carbon sources.

On Day 4 (Figure 10), the growth curves for the carbon sources change drastically. Glucose
becomes the carbon source with the highest growth by far out of the groups, with mannose and
fructose growing more significantly over two days. Dulcitol stays about the same, while mannitol
and maltitol grow slightly more.
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FIG 11: A graph showing all the data points for Day 6 of the cycle for all carbon sources.

By the final day of the growth curve cycle (Figure 11), glucose is still the highest growing
carbon source on the growth curve, followed by maltitol and xylitol. Fructose and mannose
decrease a little, while the other carbon sources stay around the same range as day 4. While all the
carbon sources had some level of growth in the six-day growth curve cycle, glucose was the clear
number one option that Mycoplasma pneumoniae used to growth at a more exponential rate.
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Statistical Analysis
Statistical analysis was done to find if the carbon sources were significant compared to no
carbon source and glucose. Using the program GraphPad Prism, these tests were able to be done
once data was added for comparisons. A Dunnett’s test was done to compare a number of
treatments with a single control to see that difference in the groups. When a Two-Way ANOVA
test has significant findings, it doesn’t show which pairs are significant compared to other pairs.
A Dunnett’s test can be used after an ANOVA test run the pairs to find the significance, if any can
be found.
A Two-Way ANOVA test was done for no carbon source vs. carbon sources and glucose
vs. carbon sources. A Dunnett’s test was done afterwards to see if there is any significance in the
carbon sources tested and compare these multiple comparisons. Comparing tests with no carbon
sources to all the other carbon sources (Table 1) gave us data that the only carbon source that was
statistically significant was glucose. While other carbon source grew in the condition the culture
flasks, they were calculated to not be as significant as glucose. Comparing tests glucose to all the
other carbon sources (Table 2) gave us data that the only carbon source that was not statistically
significant was maltitol. While maltitol grew in the condition the culture flasks, it was calculated
to not be as significant as glucose or the other carbon sources. Comparing tests glucose to all the
other carbon sources (Table 2) gave us data that the only carbon source that was not statistically
significant was maltitol. While maltitol grew in the condition the culture flasks, it was calculated
to not be as significant as glucose or the other carbon sources. Comparing tests with glucose to all
the other carbon sources (Table 3) only on day 6 gave us data that the only carbon source that was
not statistically significant was maltitol.
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TABLE 1: Two-Way Anova of carbon sources comparing No Carbon Source against all the carbon sources

Hexose sugars, pentose sugars, and sugar alcohols. A Dunnett’s test was also done to see multiple comparisons
between the carbon sources. The mean difference, adjusted p-value, and if the carbon source is significant are shown
in the table.
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TABLE 2: Two-Way Anova of carbon sources comparing Glucose against all the carbon sources

Hexose sugars, pentose sugars, and sugar alcohols. A Dunnett’s test was also done to see multiple comparisons
between the carbon sources. The mean difference, adjusted p-value, and if the carbon source is significant are shown
in the table.

32
TABLE 3: One-Way Anova of carbon sources comparing Glucose against all the carbon sources –

Hexose sugars, pentose sugars, and sugar alcohols – on Day 6 only. A Dunnett’s test was also done to see multiple
comparisons between the carbon sources. The mean difference, adjusted p-value, and if the carbon source is significant
are shown in the table.

While maltitol grew in the condition the culture flasks, it was calculated to not be as
significant as glucose. A simplified version of the statistical analysis (Table 4) corroborated with
the previous tests that comparing tests with no carbon sources to all the other carbon sources gave
us data that the only carbon source that was statistically significant was glucose.

33
TABLE 4: Dunnett’s Multiple Comparison Tests

Dunnett's Multiple Comparison Tests

Mean Difference Significant?

Adjusted P-Value

0.001 OD No Carbon Source vs. 0.001 OD Fructose

0.0004625

No

0.9999

0.001 OD No Carbon Source vs. 0.001 OD Mannose

0.0001817

No

0.9999

0.001 OD No Carbon Source vs. 0.001 OD Rhamnose

0.0001167

No

0.9999

0.001 OD No Carbon Source vs. 0.001 OD Sorbose

-0.001567

No

0.9997

0.001 OD No Carbon Source vs. 0.001 OD Galactose

-0.00105

No

0.9998

0.001 OD No Carbon Source vs. 0.001 OD Fucose

-0.0008583

No

0.9999

0.001 OD No Carbon Source vs. 0.001 OD Glucose

-0.02825

Yes

0.0017

0.001 OD No Carbon Source vs. 0.001 OD Arabinose

-0.000875

No

0.9998

0.001 OD No Carbon Source vs. 0.001 OD Xylose

-0.0006667

No

0.9999

0.001 OD No Carbon Source vs. 0.001 OD Ribose

-0.001375

No

0.9997

0.001 OD No Carbon Source vs. 0.001 OD Dulcitol

-0.003142

No

0.9993

0.001 OD No Carbon Source vs. 0.001 OD Inositol

-0.001637

No

0.9997

0.001 OD No Carbon Source vs. 0.001 OD Maltitol

-0.01238

No

0.4587

0.001 OD No Carbon Source vs. 0.001 OD Mannitol

-0.002783

No

0.9994

0.001 OD No Carbon Source vs. 0.001 OD Sorbitol

-0.0021

No

0.9996

0.001 OD No Carbon Source vs. 0.001 OD Xylitol

5.833e-005

No

0.9999

0.001 OD No Carbon Source vs. 0.001 OD Glycerol

-0.007208

No

0.9522

A simplified version of Dunnett’s Multiple Comparison Tests showing the mean difference, adjusted p-value, and if
the carbon source is significant or not.
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DISCUSSION
Carbon Sources Trials
For the trials with hexose sugars (Figure 5), fructose, mannose, rhamnose, sorbose,
galactose, and fucose all showed growth over the 6-day cycle. Sorbose, galactose, fucose, and
rhamnose were observed on day 4 reaching their highest peak before staying about even for day 6.
Galactose has an extremely low ability to incorporate in vivo, due to either the lack of a proper
membrane uptake system, or the UDP-glucose is the source for UDP-galactose in vivo by
epimerization (88, 89). Fructose and mannose showed that after day 4 a slight dip in their growth
as they were going on a downward trend by day 6. Glucose showed the same growth on day 2 as
the other hexose sugars tested, but by day 4 saw a massive jump in growth that far surpassed the
other carbon sources. This data concurs with Wodke’s (86) findings, as while in silico,
mathematical models, there is no difference in energy yield for Mycoplasma pneumoniae growth
on different carbon sources. However, in vivo, observed in a living organism, the doubling times
differed considerably, and only glucose and mannose allowed for healthy growth. Mycoplasma
pneumoniae grew more proficiently with the help of glucose then any of the other hexose sugars.
While the other hexose sugars saw considerable growth, they were not at the range that glucose
saw in the growth curve cycle.
Glucose being the hexose sugar that grew the most is consistent with previous studies that
were done into Mycoplasma pneumoniae carbon source utilization. While mannose and the other
hexose sugars have moderate to little growth, it is not as efficient and stable as what glucose
provides for the bacteria’s processes and metabolism. The pathway for glucose is defined, and
Mycoplasma pneumoniae seems to rely on this more than most other carbon sources to go into
glycolysis and other systems.
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The pentose sugar trials (Figure 6) showed a consistent growth for arabinose, xylose, and
ribose. Ribose showed the most growth on day 2, before becoming even with arabinose and xylose.
By day 6 the pentose sugars had evened out at positive rate, showing that the growth was steady
throughout the 6-day cycle. While not as massive a growth as glucose previously, these carbon
sources were shown to be able to be utilized by Mycoplasma pneumoniae. While the glucosespecific uptake protein (MPN207) has high copy numbers (∼385/cell), the known transport
proteins for other sugars (fructose, ribose, mannitol, mannose, glycerol, G3P, and ascorbate) are
8-20 times less abundant. To allow for pertinent growth of Mycoplasma pneumoniae on fructose
in vivo, for example, the cells have to be adapted over several successive passages to show any
substantial overexpression of proteins involved in fructose import and metabolism (85).
Pentose sugars grew as well as hexose sugars, but glucose is still the sugar that is most
efficiently used by Mycoplasma pneumoniae. Out the tested pentose sugars, only ribose had a
carbon source pathway that was able to be found to be dependable to the study. Ribose is theorized
to be a carbon source that this bacterium is able to use competently. However, it seems from this
study and others of a similar to it, that glucose is still the preferred carbon source to be used by
this lung bacteria.
The sugar alcohols that were tested (Figure 7) showed a wide range of growth between the
carbon sources that were tested. Maltitol showed the most growth by day 6, while xylitol showed
the least amount of growth by day 6. Glycerol and dulcitol reached their highest peak of growth
by day 4, steadying by day 6, while xylitol, sorbitol, and mannitol were going in a downward trend
by day 6. Maltitol and inositol stayed in positive growth throughout, never losing growth. Glycerol
and maltitol saw the most growth out of all the sugar alcohols over the six-day cycle, with maltitol
growing slightly more than glycerol.
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While glycerol is a known carbon source that Mycoplasma pneumoniae can utilize, the fact
the maltitol grew is interesting. Maltitol is not a carbon source that other studies and findings noted
as a potential carbon source for Mycoplasma pneumoniae to use, but with this data the possibility
of future testing with maltitol is definitely a prospect of future testing. For comparison, Grembecka
(90) found that sugar alcohols, such as maltitol, were found to increase mineral bioavailability in
humans and rats. Maltitol is partially digested in the intestines, and a non-absorbed part is
metabolized by colonic bacteria in the lower gut. Its absorption ranges from 5 to 80%, but it must
be proceeded by hydrolysis which leads to glucose and sorbitol. It is slowly digested in the small
intestine and the non-absorbed part passes to the colon where it undergoes fermentation by bacteria
(90).

Maltitol Utilization
Maltitol is a common sugar alcohol used as a sugar replacement that is found in many
sweeteners for foods and drinks we consume in our society (91). After ingestion, maltitol is slowly
hydrolyzes by the enzymes of the small intestine into its constituent monomers, glucose and
sorbitol (92). It has a very slow digestion rate because it is fermented in the colon (91). This is
similar to Mycoplasma pneumoniae, as glucose and sorbitol are carbon sources that can be utilized
in some way. Mycoplasma pneumoniae is known to use glucose and glycerol, and its pathways for
utilization are well known and covered in many studies. Maltitol, however, has not seen the same
research. The enzymes and pathways needed to be utilized by Mycoplasma pneumoniae’s
processes are not well documented at this present time. Further studies into maltitol may be clear
up how it is able to be utilized so efficiently by Mycoplasma pneumoniae.
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Glycerol being a carbon source that Mycoplasma pneumoniae is able to use efficiently is
consistent with other studies. However, maltitol showing as much growth as glucose and glycerol
is a new factor that may have to be taken into account in future studies of a similar nature. Maltitol
as a carbon source that is able to be utilized by Mycoplasma pneumoniae is new data that is not
been explored in other studies involving the bacteria. Common in most chewing gums, maltitol as
a carbon source that Mycoplasma pneumoniae may be able to use efficiently is still new
information (93). While its growth was unprecedented, the statistical analysis states that it is not a
statistically significant carbon source for Mycoplasma pneumoniae. Further studies can be done to
look into the how this is able to occur. A carbon source pathway for maltitol can’t be accurately
defined at the moment, which is a step that needs to be looked into future studies into carbon
sources. The enzymes and mechanisms for this carbon source to be used by Mycoplasma
pneumoniae are perhaps there, albeit not discovered fully yet.
Mannitol as a carbon source seems to be present in Mycoplasma pneumoniae, even though
the substrate cannot be used by the bacteria (24). Glycerol showing positive growth is comparable
to other studies that show that glycerol is one of the few carbon sources to already be known to
utilized by Mycoplasma pneumoniae (25). It uses glycerol metabolism, which its first component
is the glycerol facilitator encoded by glpF gene. The importance of glycolysis for most mollicutes,
such as Mycoplasma pneumoniae, is underlined by the lack of the oxidative part of the pentose
phosphate pathway and of the citric acid cycle. Mycoplasma pneumoniae grows the fastest with
glucose; though, with the abundance of glycerol and glycerol-containing molecules in the
bacterium’s environment and the role of glycerol as the trigger of one of the few regulatory proteins
indicate that glycerol might be the preferred carbon source (86).
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Reductive Evolution & Statistical Analysis
The role of reductive evolution in the utilization of carbon sources by Mycoplasma
pneumoniae may have been seen in this study. While most of the carbon sources were able to be
utilized by in the well plate tests, not all of the carbon sources were not able to be grown in the
growth curve tests. This can be hypothesized as a result of reductive evolution, as even though the
paths for those carbon sources are there for them to be used, the redundancy of those metabolic
paths are not beneficial for Mycoplasma pneumoniae. Certain pathways that are available for most
bacteria seem to not be advantageous for use, resulting in fewer carbon sources being able to be
utilized by Mycoplasma pneumoniae better, if not at all.
The significance of the statistical analysis in this study show some notable data of the
carbon sources. With the ranges of the carbon source fluctuating in different ways, especially on
different days on the six-day growth curves, the findings varied per day. Xylitol, for example, grew
at an increased rate for the first 4 days of the cycle, the decreasing by day 6. This could be because
of two notions; by day 6, Mycoplasma pneumoniae no longer can use this carbon source, or the
carbon source was no longer effective and slowly degraded over time. With this shifting range of
data, the graphs with data points showing the carbon sources by days was devised to show the
growth of the carbon sources in a more comparable approach. Both approaches to graphs in this
study have its advantages and disadvantages, both showing the data in new light so it can be used
to come to new conclusions.
Glycerol is one of the known carbon sources that is able to be utilized fully by Mycoplasma
pneumoniae. The complex process of being synthesized for use in the bacteria has a variety of
ways for it to happen. The outcome could either result in glycerol phosphate that can be used in
other processes, or it can take a longer path to eventually used for the biosynthesis of
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phospholipids. No matter what, glycerol is clearly a significant carbon source for Mycoplasma
pneumoniae that is allows in thrive in the human lung.
The hypothesis in this study was shown to be not supported. While other carbon sources
were able to be utilized by Mycoplasma pneumoniae, they were not as efficient as glucose. A twoway ANOVA that was done testing No Carbon Source against other carbon sources showed that
glucose was the only carbon source that was significant. A two-way ANOVA of glucose against
other carbon sources showed they were all significant, except for maltitol. It can be assumed with
the data that hexose sugars, pentose sugars, and sugar alcohols that are similar to glucose and
glycerol can be utilized by Mycoplasma pneumoniae. Theoretically, these carbon sources can be
used to develop alternate treatments to treat afflictions that infect the lungs. These carbon sources
can be possibly be used to counter diseases and difficulties caused by Mycoplasma pneumoniae.
This could especially be beneficial for patients that inadvertently acquire symptoms in research
and healthcare settings in being able to diagnose and treat this before it gets too severe.
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MATERIALS & METHODS
Analysis of carbon sources and their effect on Mycoplasma pneumoniae
All procedures that are to be used in this experiment are adapted and based on scholarly studies
by mentor Dr. Sebastian R. Schmidl, as well as direct suggestions from him (12, 25, 82).
Mycoplasma pneumoniae will be stored in -80°C freezer in cryotubes to be used for these tests.
Cryotubes were prepared beforehand by taking samples acquired at placing them at a temperature
where they would not degrade over time. M. pneumoniae was tested in well plates to with different
carbon source concentrations to measure their growth. Optical density was also calculated to be
able to add accurate amounts of the mycoplasma to the carbon sources. The use of optical density
was to see the cell growth of different carbon sources in a 6-8-day cycle. Growth curves are also
made to test optical density of an eight-day period. Mycoplasma pneumoniae will be tested with
carbon sources to see how they affect their growth. Growth curves containing no carbon sources
will be tested as a control. A ThermoScientific Herasafe KS, Class II safety cabinet will be the
main equipment used to do experiments.
M. pneumoniae cells will be harvested in 1.5 ml phosphate-buffered saline (PBS) pH 7.4. The
cells will then be spun down in a centrifuge for 5 minutes at 10,000 x g and 4°C and the supernatant
is then to be discarded. The cells will then be washed again in 1 ml PBS pH 7.4 and centrifuged
for another 5 minutes at 10,000 x g and 4C. The pellet then needs to be resuspended in 1 ml and
800 l water of the solution will be used for determination of optical density at 550 nm, which is
the best wavelength to test for density of this bacteria.
For these growth experiments, the number of cells corresponding to different OD550 units in a
final volume of 1 ml is going to be used. The cells are to be pelleted by centrifugation at 10,000 x
g for 5 minutes at 4°C and the supernatant then discarded. The washed cells then are going to be
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resuspended in MP medium 900 l. One ml of MP medium is to be plated into the wells of a sterile
24-well cell culture plate. The OD550 added to the wells are different according to the carbon
source that is to be tested in that trial. Cells will be incubated for 3-4 days at 37°C.
When the incubation period is done, the well plates will be taken out of the incubator and
observed to see a change in color. A lighter change in color, such as an orange or yellow, will
signify that Mycoplasma pneumoniae in the wells were able to grow in the different carbon source
solutions that will be presented in the wells.

Measuring optical density
Carbon source preparation procedures that are to be used are adapted and based on
scholarly studies by mentor Dr. Sebastian R. Schmidl, as well as direct suggestions from him and
discussion with fellow master students in the lab (65, 94, 95). Similar to glucose, hexoses and
pentoses – such as fructose, galactose, mannose, rhamnose, sorbose, fucose, sorbose, arabinose,
xylose, and ribose – and glycerol, sugar alcohols – such as dulcitol, inositol, mannitol, sorbitol,
xylitol, and maltitol.
Mycoplasma pneumoniae is to be placed into 50-milliliter tube. The tube was then filled
with a solution of MP medium – Beef Heart Infusion Broth, Yeast extract, Deoxyribonucleic acid,
Phenol red, and Agar – at a final pH of 7.8 (25°C). horse serum, penicillin, and the specific carbon
source that will be tested in the trials. The calculations – (Number of microliters in tube) (Starting
OD) times X x (OD x 2) – are based on the optical density of the Mycoplasma pneumoniae cells
to be recorded from testing will help determine the appropriate amount of the cells to place into
the flask. The starting optical density of all trials is to be 0.001.
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Mycoplasma pneumoniae cells are to be thawed from their cryotubes in -80°C freezer by
putting them on ice. The tubes are then to be mixed gently and pipetted 400 l into sterile 1.5 ml
microcentrifuge tubes. These cells will be centrifuged for 5 minutes at 10,000 x g and 4°C and the
supernatant will be discarded. The pellet that remains will be resuspended in 800 l of PBS pH
7.4 and the cells will be centrifuged for 5 minutes at 10,000 x g and 4°C for a second time. After
discarding the supernatant, the pellet will be resuspended in 400 l PBS pH 7.4.
The pellet resuspended in 400 l PBS pH 7.4 will then be placed into a spectrophotometer
cuvette and an additional 400 l PBS pH 7.4 will be added to the cuvette, for a total of 800 l.
Another 800 l PBS pH 7.4 will be placed in a reference blank cuvette. This reference blank will
be used as a control to be referenced against carbon sources to be tested. Specific cell culture
volumes to be used are based the OD550 and will be inoculated into the modified MP medium. This
medium will consist of 20% horse serum, 300 l penicillin, and the specific carbon source volume
will be added to these mediums. The MP medium is prepared because it is the best solution for
carbon sources to be tested in. Three empty cell culture flasks – labeled Day 2, Day 4, and Day 6
– are to be prepared. The 3 cell culture flasks will each have 10 ml of Hayflick medium containing
the appropriate carbon source. Incubation of these flasks will be for 6 days at 37°C and checked
and recorded every 2 days. Every 2 days, the cells with be harvested according to the correct day
flask by using a cell scraper and scraping the growing cells from side of the flask. They are to be
harvested in 1 ml PBS pH 7.4 and placed in a sterile 2 ml microcentrifuge tube. The cells will then
be centrifuged for 5 minutes at 10,000 x g and 4°C and supernatant is to then be discarded. The
pellet will be resuspended in 1 ml PBS pH 7.4 and 800 l of this will be transferred into a cell
suspension in a spectrophotometer cuvette. The OD 550 will be measured alongside an 800 ul PBS
pH 7.4 reference blank. The OD550 will recorded for the specific carbon source. The same
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procedure will be then done for Day 4 and Day 6 for all carbon sources tested in the current cycle.
All data will then be put together for use in growth curves and statistical analysis.

Statistical Analysis
Statistical analysis was done to find if the carbon sources were significant compared to no
carbon source and glucose. Using the program GraphPad Prism, these tests were able to be done
once data was added for comparisons. A Dunnett’s test was done to compare a number of
treatments with a single control to see that difference in the groups. When a Two-Way ANOVA
test has significant findings, it doesn’t show which pairs are significant compared to other pairs.
A Dunnett’s test can be used after an ANOVA test run the pairs to find the significance, if any can
be found.
A Two-Way ANOVA test was done for no carbon source vs. carbon sources and glucose
vs. carbon sources. A Dunnett’s test was done afterwards to see if there is any significance in the
carbon sources tested and compare these multiple comparisons.
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FIGURES & DATA [APPENDIXES]

S1: List of trials and the numerical data for the Hexose sugars tested at OD550 in Figure 5.
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S2: List of trials and numerical data for Pentose sugars tested at OD550 in Figure 6.
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S3: List of trials and numerical data for Alcohol sugars tested at OD550 in Figure 7.
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